AI-READI consortium launches groundbreaking diabetes data study

Researchers today (Nov. 8, 2024) are releasing the flagship dataset from an ambitious study of biomarkers and environmental factors that might influence the development of type 2 diabetes.

Pharmalittle: We’re reading about a Novo Nordisk deal, a Regeneron setback, and more

Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because that oh-so familiar routine of online

March 25, 2024

Pentixapharm Receives EUR 6.77 Million for Intangible Assets Formerly Developed by Glycotope – Biotech Investments

EQS-News: Pentixapharm Holding AG / Key word(s): Agreement Pentixapharm Receives EUR 6.77 Million for Intangible Assets Formerly Developed by Glycotope 07.01.2025 / 10:30 CET/CEST The

January 8, 2025

Imbria touts PhII success in hypertrophic cardiomyopathy, adding fuel to overall efficacy profile

Imbria Pharmaceuticals’ partial fatty acid oxidation inhibitor improved outcomes in Phase II non-obstructive hypertrophic cardiomyopathy patients, with the company noting that the asset’s efficacy could

November 8, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.